<DOC>
	<DOC>NCT01289678</DOC>
	<brief_summary>Assess the immunotherapy benefit of interleukin-2 in acute myelogenous leukemia treatment during lymphocyte recovery.</brief_summary>
	<brief_title>Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Famotidine</mesh_term>
	<criteria>Confirmed hematopathology diagnosis of AML receiving marrow suppressive treatment Total WBC recovery of 500 mm3 prior to IL2 treatment Platelet count of at least 20,000 mm3 prior to starting IL2 treatment Active infection controlled prior to starting IL2 treatment Stable systolic blood pressure &gt; 90mm Hg prior to starting IL2 treatment O2 saturation &gt;90% prior to starting treatment Stable cardiopulmonary status prior to starting IL2 treatment Serum creatinine &lt; or equal to 2.0 mg/dl Total bilirubin and AST &lt;3x upper limits normal Acute Promyelocytic Leukemia Active thrombocytopenic bleeding Cardiac ejection fraction below 45% Pregnancy and/or lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>acute myelogenous leukemia</keyword>
	<keyword>interleukin-2</keyword>
</DOC>